• 1
    Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000; 21: 48897.
  • 2
    Towheed TE. Published meta-analyses of pharmacological therapies for osteoarthritis. Osteoarthritis Cartilage 2002; 10: 8367.
  • 3
    Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992; 14: 15476.
  • 4
    Bandolier. Oxford league table of analgesics in acute pain. URL:
  • 5
    Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 68391.
  • 6
    Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses [papers]. BMJ 2003; 326: 4726.
  • 7
    Riedemann PJ, Bersinic S, Cuddy LJ, Torrance GW, Tugwell PX. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol 1993; 20: 2095103.
  • 8
    Porzio F. Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. Rheumatol Int 1993; 13 Suppl 2: S1924.
  • 9
    Eccles M, Freemantle N, Mason J, and the North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998; 317: 52630.
  • 10
    Emery P, Kong SX, Ehrich EW, Watson DJ, Towheed TE. Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. Clin Ther 2002; 24: 122591.
  • 11
    McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. Cox-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol 2001; 7: 1519.
  • 12
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, and the Vioxx, Acetaminophen, Celecoxib Trial lpar;VACT) Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial [published erratum appears in JAMA 2002;287:989]. JAMA 2002; 287: 6471.
  • 13
    Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 310211.
  • 14
    Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21: 206579.
  • 15
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 192933.
  • 16
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 9549.
  • 17
    Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 61923.
  • 18
    US Food and Drug Administration website. URL:
  • 19
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 20
    Becker, LA. Effect size calculators. URL:∼lbecker/psy590/escalc3.htm.
  • 21
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
  • 22
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 23
    Fisher CA, Curtis SP, Resnick H, Ripley P, Leung AT, Ko AT, et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks. Arthritis Rheum 2001; 44: S135.
  • 24
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095105.
  • 25
    Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001; 23: 21327.
  • 26
    Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29: 46779.
  • 27
    Lisse J, Espinoza L, Zhao SZ, Dedhiya SD, Osterhaus JT. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci 2001; 56: 16775.
  • 28
    McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 118.
  • 29
    Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18: 4958.
  • 30
    Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al, and the Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis [published erratum appears in Rheumatology (Oxford) 2003;42:814]. Rheumatology (Oxford) 2002; 41: 105261.
  • 31
    Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al, and the Osteoarthritis Studies Group. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000; 9: 112434.
  • 32
    D ay R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al, and the Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 17817.
  • 33
    Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al, and the Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 243847.
  • 34
    Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 5307.
  • 35
    Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002; 10: 2906.
  • 36
    Zhang WY, Li Wan Po A. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis. J Clin Pharm Ther 1996; 21: 26182.
  • 37
    Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2: ii136.
  • 38
    Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004; 20: 52531.
  • 39
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. ICH harmonized tripartite guideline choice of control group and related issues in clinical trials E10. 2000. URL:
  • 40
    Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Q, et al, and the Phase III Rofecoxib Geriatric Study Group. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001; 13: 11221.
  • 41
    Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 13515.
  • 42
    Bellamy N. WOMAC Osteoarthritis index: a user's guide. London: London Health Sciences Center; 1998.
  • 43
    Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes in clinical trials. Clin Trials 2003; 1: 2331.